Which medication do I need to manage dizzy patients?

References

• Strupp M, Brandt T. Current treatment of vestibular, ocular motor disorders and nystagmus. Ther Adv Neurol Disord 2009;3:223–39.
   Google Scholar
• Griggs RC, Nutt JC. Episodic ataxias as channelopathies. Ann Neurol 1995;37:285–7.
   PubMed Web of Science ®Google Scholar
• Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia. Neurology 2004;62:17–22.
   PubMed Web of Science ®Google Scholar
• Strupp M, Zwergal A, Brandt TW. Episodic ataxia type 2. Neurotherapeutics 2007;4:267–73.
   PubMed Web of Science ®Google Scholar
• Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007;130:2484–93.
   PubMed Web of Science ®Google Scholar
• Ophoff RA, Terwindt GM, Vergouwe MN. Familial hemiplegic migraine in episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543–52.
   PubMed Web of Science ®Google Scholar
• Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004;62:1623–5.
   PubMed Web of Science ®Google Scholar
• Walter JT, Alvina K, Womack MD, Chevez C, Khodakhah K. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat Neurosci 2006;9:389–97.
   PubMed Web of Science ®Google Scholar
• Alvina K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 2010;30:7258–68.
   PubMed Web of Science ®Google Scholar
• Lohle M, Schrempf W, Wolz M, Reichmann H, Storch A. Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 – a video case report. Mov Disord 2008;23:1314–16.
   PubMedGoogle Scholar
• Wagner JN, Glaser M, Brandt T, Strupp M. Downbeat nystagmus: aetiology and comorbidity in 117 patients. J Neurol Neurosurg Psychiatry 2008;79:672–7.
   PubMed Web of Science ®Google Scholar
• Baloh RW, Spooner JW. Downbeat nystagmus. A type of central vestibular nystagmus. Neurology 1981;31:304–10.
   PubMed Web of Science ®Google Scholar
• Leigh RJ, Zee D. 2006. The neurology of eye movements, 4th edn. New York: Oxford University Press.
   Google Scholar
• Zee DS, Yamazaki N, Butler PHZ, Bücer F. Effects of ablation of flocculus and paraflocculus on eye movements in primate. J Neurophysiol 1981;46:878–99.
   PubMed Web of Science ®Google Scholar
• Etzion Y, Grossman Y. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res 2001;139:419–25.
   PubMed Web of Science ®Google Scholar
• Bense S, Best C, Buchholz HG, Wiener V, Schreckenberger M, Bartensteiner P, 18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus. Neuroreport 2006;17:599–603.
   PubMed Web of Science ®Google Scholar
• Kalla R, Glasauer S, Schautzer F. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology 2004;62:1228–9.
   PubMed Web of Science ®Google Scholar
• Kalla R, Glasauer S, Büttner U, Brandt T, Strupp M. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 2007;130:2441–51.
   PubMed Web of Science ®Google Scholar
• Glasauer S, Kalla R, Büttner U, Strupp M, Brandt T. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus. J Neurol Neurosurg Psychiatry 2005;76:451–3.
   PubMed Web of Science ®Google Scholar
• Dieterich M, Straube A, Brandt T, Paulus W, Büttner U. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry 1991;54:627–32.
   PubMed Web of Science ®Google Scholar
• Averbuch-Heller L, Tusa RJ, Fuhry L, Rottach KG, Ganser GL, Heide W, A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997;41:818–25.
   PubMed Web of Science ®Google Scholar
• Leigh RJ, Robinson DA, Zee DS. A hypothetical explanation for periodic alternating nystagmus: instability in the optokinetic-vestibular system. Ann N Y Acad Sci 1981;374:619–35.
   PubMed Web of Science ®Google Scholar
• Stahl JS, Plant GT, Leigh RJ. Medical treatment of nystagmus and its visual consequences. J R Soc Med 2002;95:235–7.
   PubMed Web of Science ®Google Scholar
• Straube A, Leigh RJ, Bronstein A, Heide W, Riordan-Eva P, Tijssen CC, EFNS task force – therapy of nystagmus and oscillopsia. Eur J Neurol 2004;11:83–9.
   PubMed Web of Science ®Google Scholar
• Straube A. Nystagmus: an update on treatment in adults. Expert Opin Pharmacother 2005;6:583–90.
   PubMed Web of Science ®Google Scholar
• Straube A. Pharmacology of vertigo/nystagmus/oscillopsia. Curr Opin Neurol 2005;18:11–14.
   PubMed Web of Science ®Google Scholar
• Brandt T, Dieterich M, Strupp M. 2005. Vertigo and dizziness – common complaints. London: Springer.
   Google Scholar
• Yeh TH, Herman P, Tsai MC, Tran-Ba Huy P, Van-den-Abbeele T. A cationic nonselective stretch-activated channel in the Reissner's membrane of the guinea pig cochlea. Am J Physiol 1998;274:C566–C76.
   Web of Science ®Google Scholar
• Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999;120:400–5.
   PubMed Web of Science ®Google Scholar
• Claes J, Van-de-Heyning PH. Medical treatment of Ménière's disease: a review of literature. Acta Otolaryngol Suppl 1997;526:37–42.
   PubMedGoogle Scholar
• James A, Thorp M. Ménière's disease. Clin Evid 2004;12:742–50.
   Google Scholar
• Strupp M, Huppert D, Frenzel C, Wagner J, Hahn A, Jahn K, Long-term prophylactic treatment of attacks of vertigo in Ménière's disease – comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol 2008;128:620–4.
   Google Scholar
• Baloh RW, Jacobson K, Winder T. Drop attacks with Ménière's syndrome. Ann Neurol 1990;28:384–7.
   PubMed Web of Science ®Google Scholar
• Jannetta PJ, Moller MB, Moller AR. Disabling positional vertigo. N Engl J Med 1984;310:1700–5.
   PubMed Web of Science ®Google Scholar
• Hüfner K, Barresi D, Glaser M, Linn J, Adrion C, Mansmann U, Vestibular paroxysmia: diagnostic features and medical treatment. Neurology 2008;71:1006–14.
   PubMed Web of Science ®Google Scholar
• Brandt T, Dieterich M. Vestibular paroxysmia: vascular compression of the eighth nerve? Lancet 1994;343:798–9.
   PubMed Web of Science ®Google Scholar
• Kanashiro AM, Alexandre PL, Pereira CB, Melo AC, Scaff M. Vestibular paroxysmia: clinical study and treatment of eight patients. Arq Neuropsiquiatr 2005;63:643–7.
   PubMedGoogle Scholar
• Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. Brain 1975;98:189–202.
   PubMed Web of Science ®Google Scholar
• Espir MLE, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970;33:528–31.
   PubMed Web of Science ®Google Scholar
• Lee JP. Superior oblique myokymia: a possible etiologic factor. Arch Ophthalmol 1984;102:1178–9.
   PubMedGoogle Scholar
• Yousry I, Dieterich M, Naidich TP, Schmid UD, Yousry TA. Superior oblique myokymia: magnetic resonance imaging support for the neurovascular compression hypothesis. Ann Neurol 2002;51:361–8.
   PubMed Web of Science ®Google Scholar
• Susac JO, Smith JL, Schatz NJ. Superior oblique myokymia. Arch Neurol 1973;29:432–4.
   PubMedGoogle Scholar
• Rosenberg MI, Glaser JS. Superior oblique myokymia. Ann Neurol 1983;13:667–9.
   PubMed Web of Science ®Google Scholar
• Hüfner K, Linn J, Strupp M. Recurrent attacks of vertigo with monocular oscillopsia. Neurology 2008;71:863.
   PubMed Web of Science ®Google Scholar
• Ehrenberger K, Felix D. Receptor pharmacological models for the therapy of labyrinthine vertigo. Acta Otolaryngol 1996;116:189–91.
   PubMed Web of Science ®Google Scholar
• Barrs DM. Intratympanic injections of dexamethasone for long-term control of vertigo. Laryngoscope 2004;114:1910–14.
   PubMed Web of Science ®Google Scholar
• Yilmaz I, Yilmazer C, Erkan AN, Aslan SG, Ozluoglu LN. Intratympanic dexamethasone injection effects on transient-evoked otoacoustic emission. Am J Otolaryngol 2005;26:113–17.
   PubMed Web of Science ®Google Scholar
• Garduno-Anaya MA, Couthino De TH, Hinojosa-Gonzalez R, Pane-Pianese C, Rios-Castaneda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005;133:285–94.
   PubMed Web of Science ®Google Scholar
• Alles MJ, der Gaag MA, Stokroos RJ. Intratympanic steroid therapy for inner ear diseases, a review of the literature. Eur Arch Otorhinolaryngol 2006;263:791–7.
   PubMed Web of Science ®Google Scholar
• Reason JT. Motion sickness adaptation: a neural mismatch model. J R Soc Med 1978;71:819–29.
   PubMed Web of Science ®Google Scholar
• Dichgans J, Brandt T. 1978. Visual-vestibular interaction: effects on self-motion perception and postural control. In: Held R, Leibowitz HW, Teuber HL, editors. Handbook of sensory physiology, Vol VIII, Perception. New York: Springer. p.755–804.
   Google Scholar
• Wood CD, Graybiel A, McDonough R. Human centrifuge studies on the relative effectiveness of some anti-motion sickness drugs. Aerospace Med 1966;37:187–90.
   PubMedGoogle Scholar
• Stahl JS, Averbuch-Heller L, Leigh RJ. Acquired nystagmus. Arch Ophthalmol 2000;118:544–9.
   PubMedGoogle Scholar
• Leigh RJ, Das VE, Seidman SH. A neurobiological approach to acquired nystagmus. Ann N Y Acad Sci 2002;956:380–90.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Wilms H. Clinical spectrum and physiology of palatal tremor. Mov Disord 2002;17(Suppl 2):63–6.
   Google Scholar
• Kim JS, Moon SY, Choi KD, Kim JH, Sharpe JA. Patterns of ocular oscillation in oculopalatal tremor: imaging correlations. Neurology 2007;68:1128–35.
   PubMed Web of Science ®Google Scholar
• Moon SY, Park SH, Hwang JM, Kim JS. Oculopalatal tremor after pontine hemorrhage. Neurology 2003;61:1621.
   PubMedGoogle Scholar
• Lopez LI, Bronstein AM, Gresty MA, DuBoulay EP, Rudge P. Clinical and MRI correlates in 27 patients with acquired pendular nystagmus. Brain 1996;119:465–72.
   PubMed Web of Science ®Google Scholar
• Shery T, Proudlock FA, Sarvananthan N, McLean RJ, Gottlob I. The effects of gabapentin and mementine in acquired and congenital nystagmus: a retrospective study. Br J Ophthalmol 2006;90:839–43.
   PubMed Web of Science ®Google Scholar
• Starck M, Albrecht H, Pöllmann W, Dieterich M, Straube A. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 2010;257:322–7.
   PubMed Web of Science ®Google Scholar
• Thurtell MJ, Joshi AC, Leone AC, Tomsak RL, Kosmorsky GS, Stahl JS, Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Am Neurol Assoc 2010;67:676–80.
   Google Scholar
• Brandt T, Dieterich M. 1993. Preliminary classification of vestibular brain-stem disorders. In: Caplan LR, Hopf HC, editors. Brain-stem localization and function. Berlin: Springer. p. 79–91.
   Google Scholar
• Leigh RJ, Zee DS. 1999. The neurology of eye movements, 3rd edn. New York: Oxford University Press.
   Google Scholar
• Self J, Lotery A. A review of the molecular genetics of congenital idiopathic nystagmus (CIN). Ophthalmic Genet 2007;28:187–91.
   PubMed Web of Science ®Google Scholar
• McLean R, Proudlock F, Thomas S, Degg C, Gottlob I. Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin. Ann Neurol 2007;61:130–8.
   PubMed Web of Science ®Google Scholar
• Smith WK, Sankar V, Pfleiderer AG. A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease. J Laryngol Otol 2005;119:102–5.
   PubMed Web of Science ®Google Scholar
• Lange G, Maurer J, Mann W. Long-term results after interval therapy with intratympanic gentamicin for Ménière's disease. Laryngoscope 2004;114:102–5.
   PubMed Web of Science ®Google Scholar
• De SA, Dispenza F, De DG, Caruso A, Taibah A, Sanna M. Intratympanic gentamicin: a 1-day protocol treatment for unilateral Ménière's disease. Am J Otolaryngol 2007;28:289–93.
   PubMedGoogle Scholar
• Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA. Intratympanic gentamicin for Ménière's disease: a meta-analysis. Laryngoscope 2004;114:2085–91.
   PubMed Web of Science ®Google Scholar
• Carey JP, Hirvonen T, Peng GC, Della Santina CC, Cremer PD, Haslwanter T, Changes in the angular vestibulo-ocular reflex after a single dose of intratympanic gentamicin for Ménière's disease. Auris Nasus Larynx 2002;956:581–4.
   Google Scholar
• Flanagan S, Mukherjee P, Tonkin J. Outcomes in the use of intratympanic gentamicin in the treatment of Ménière's disease. J Laryngol Otol 2006;120:98–102.
   PubMedGoogle Scholar
• Colletti V, Carner M, Colletti L. Auditory results after vestibular nerve section and intratympanic gentamicin for Ménière's disease. Otol Neurotol 2007;28:145–51.
   PubMed Web of Science ®Google Scholar
• Takumida M, Kakigi A, Takeda T, Anniko M. Meniere's disease: a long-term follow-up study of bilateral hearing levels. Acta Otolaryngol 2006;126:921–5.
   PubMed Web of Science ®Google Scholar
• Huppert D, Strupp M, Brandt T. Long-term course of Ménière's disease revisited. Acta Otolaryngol 2010;130:644–51.
   PubMed Web of Science ®Google Scholar
• Ödkvist LM, Bergenius J. Drop attacks in Ménière's disease. Acta Otolaryngol Suppl 1988;455:82–5.
   PubMedGoogle Scholar
• Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009;72:1630–3.
   PubMed Web of Science ®Google Scholar
• Sekitani T, Imate Y, Noguchi T, Inokuma T. Vestibular neuronitis: epidemiological survey by questionnaire in Japan. Acta Otolaryngol Suppl 1993;503:9–12.
   PubMedGoogle Scholar
• Schulz P, Arbusow V, Strupp M, Dieterich M, Rauch E, Brandt T. Highly variable distribution of HSV-1 specific DNA in human geniculate, vestibular, and spiral ganglia. Neurosci Lett 1998;252:139–42.
   PubMed Web of Science ®Google Scholar
• Arbusow V, Schulz P, Strupp M, Dieterich M, v. Reinhardstoettner A, Rauch E, et al. Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol 1999;46:416–19.
   PubMed Web of Science ®Google Scholar
• Theil D, Arbusow V, Derfuss T, Strupp M, Pfeiffer M, Mascolo A, Prevalence of HSV-1 lat in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes. Brain Pathol 2001;11:408–13.
   PubMedGoogle Scholar
• Theil D, Derfuss T, Strupp M, Gilden HD, Arbusow V, Brandt T. Latent herpes-virus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003;163:2179–84.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Segerer S, Herberger S, Sinicina I, Hüfner K, Ebelt K, Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathol 2007;17:389–98.
   PubMed Web of Science ®Google Scholar
• Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M, Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004;351:354–61.
   PubMed Web of Science ®Google Scholar
• Goudakos JK, Markou KD, Franco-Vidal V, Vital V, Tsaligopoulos M, Darrouzet V. Corticosteroids in the treatment of vestibular neuritis: a systematic review and meta-analysis. Otol Neurotol 2010;31:183–9.
   PubMed Web of Science ®Google Scholar
• Vollertsen RS, McDonald T, Younge BR, Banks PM, Stanson AW, Ilstrup DM. Cogan's syndrome: 18 cases and a review of the literature. Mayo Clin Proc 1986;61:344–61.
   PubMed Web of Science ®Google Scholar
• Allen NB, Cox CC, Cobo M, Kisslo J, Jacobs R, McCallum RM, Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestation of Cogan syndrome. Am J Med 1990;88:296–301.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Vinceneux P, Bouccara D, Sterkers O, Bodelet B. Methotrexate as a steroid-sparing agent in Cogan's syndrome. Arthritis Rheum 1994;38:1348–9.
   Google Scholar
• Zierhut M, Schlote T, Stübiger N, Daikeler T, Kötter I, Bless D, Cogan-I-Syndrom: Klinik, Therapie und Prognose. Ophthalmologe 2000;97:197–202.
   PubMed Web of Science ®Google Scholar
• Neuhauser H, Leopold M, von Bevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 2001;56:436–41.
   PubMed Web of Science ®Google Scholar
• Brandt T. A chameleon among the episodic vertigo syndromes: ‘migrainous vertigo’ or ‘vestibular migraine’. Cephalalgia 2004;24:81–2.
   PubMed Web of Science ®Google Scholar
• Brandt T, Strupp M. Migraine and vertigo classification, clinical features, and special treatment considerations. Headache Currents 2006;3:12–19.
   Google Scholar
• Furman JM, Marcus DA, Balaban CD. Migrainous vertigo: development of a pathogenetic model and structured diagnostic interview. Curr Opin Neurol 2003;16:5–13.
   PubMed Web of Science ®Google Scholar
• Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia 2004;24:83–91.
   PubMed Web of Science ®Google Scholar
• Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 1999;246:883–92.
   PubMed Web of Science ®Google Scholar
• Lempert T, Neuhauser H. Migrainous vertigo. Neurol Clin 2005;23:715–30.
   PubMed Web of Science ®Google Scholar
• Furman JM, Jacob RG. Psychiatric dizziness. Neurology 1997;48:1161–6.
   PubMed Web of Science ®Google Scholar
• Strupp M, Glaser M, Karch C, Rettinger N, Brandt T. The most common form of dizziness in middle age: phobic postural vertigo. Nervenarzt 2003;74:911–14.
   PubMedGoogle Scholar
• Brandt T, Dieterich M. Phobischer Attacken-Schwankschwindel, ein neues Syndrom? Münch Med Wochenschr 1986;128:247–50.
   Google Scholar
• Kapfhammer HP, Mayer C, Hock U, Huppert D, Dieterich M, Brandt T. Course of illness in phobic postural vertigo. Acta Neurol Scand 1997;95:23–8.
   PubMedGoogle Scholar
• Huppert D, Kunihiro T, Brandt T. Phobic postural vertigo (154 patients): its association with vestibular disorders. J Audiol 1995;4:97–103.
   Google Scholar
• Brandt T, Huppert D, Dieterich M. Phobic postural vertigo: a first follow-up. J Neurol 1994;241:191–5.
   PubMed Web of Science ®Google Scholar
• Huppert D, Strupp M, Rettinger N, Hecht J, Brandt T. Phobic postural vertigo. A long-term follow-up (5 to 15 years) of 106 patients. J Neurol 2005;252:564–9.
   PubMed Web of Science ®Google Scholar
• Wood CD, Graybiel A, Kennedy RS. Comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. Aerospace Med 1966;37:259–62.
   PubMedGoogle Scholar
• Wood CD, Graybiel A. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions. Aerospace Med 1968;39:1341–4.
   PubMedGoogle Scholar
• Wood CD, Graybiel A. Evaluation of anti-motion sickness drugs: a new effective remedy revealed. Aerospace Med 1970;41:932–3.
   PubMedGoogle Scholar